Analysts Set Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) PT at $5.00

Posted by George Bondi on Sep 20th, 2026

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Get Free Report) has been given a consensus rating of “Hold” by the five analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $5.00.

CTXR has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating on shares of Citius Pharmaceuticals in a report on Wednesday, August 19th. Citigroup reissued a “buy” rating on shares of Citius Pharmaceuticals in a report on Wednesday, August 19th. Wall Street Zen downgraded Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, June 24th.

Get Our Latest Report on Citius Pharmaceuticals

Citius Pharmaceuticals Stock Performance

Citius Pharmaceuticals stock opened at $0.60 on Friday. Citius Pharmaceuticals has a fifty-two week low of $0.47 and a fifty-two week high of $2.19. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.40 and a current ratio of 0.84. The stock has a market cap of $16.47 million, a P/E ratio of -0.36 and a beta of 1.00. The firm’s fifty day moving average price is $0.59 and its 200-day moving average price is $0.66.

Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.02. On average, equities research analysts expect that Citius Pharmaceuticals will post -2.03 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Citius Pharmaceuticals

An institutional investor recently bought a new stake in Citius Pharmaceuticals stock. BlackRock Inc. acquired a new stake in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 69,850 shares of the company’s stock, valued at approximately $42,000. BlackRock Inc. owned approximately 0.25% of Citius Pharmaceuticals as of its most recent filing with the SEC. 16.88% of the stock is currently owned by institutional investors and hedge funds.

About Citius Pharmaceuticals

(Get Free Report)

Citius Pharmaceuticals, Inc (NASDAQ: CTXR) is a specialty pharmaceutical company focused on developing and commercializing products for underserved areas of healthcare. The company has historically concentrated on anti-infective therapies, oncology treatments and supportive-care products, with an emphasis on therapies that address significant unmet medical needs.

Citius’ lead programs have included Mino-Lok, an investigational antibiotic lock solution designed to help salvage infected central venous catheters by treating catheter-related bloodstream infections while preserving the catheter.